CytomX Therapeutics announces business update, 2026 milestones

CytomX Therapeutics (CTMX) announced a business update and anticipated milestones for 2026. Clinical Program Updates and 2026 Milestones: Varsetatug masetecan: Varseta-M Phase 1 dose expansions across the 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg doses, administered every three weeks are ongoing with a focus on selecting a dose or doses for a potential registrational study in advanced CRC. Total Phase 1 study enrollment is projected to reach approximately 100 patients by the planned Varseta-M Phase 1 update in Q1 2026. The Company aims to align with the FDA in 2026 on a potential registrational study design for Varseta-M monotherapy in advanced CRC. A Phase 1 Varseta-M combination study with bevacizumab in CRC is expected to start in Q1 2026, data from which is intended to inform potential late-phase development in earlier lines of CRC. CX-801: The CX-801 Phase 1 study is ongoing with a focus in advanced melanoma. CX-801 monotherapy dose escalation has reached the fourth dose level. CX-801 monotherapy has been well tolerated at dose levels exceeding the approved dose of unmasked IFNalpha2b. CX-801 monotherapy biomarker data in advanced melanoma patients were presented at the 2025 Society of Immunotherapy of Cancer Annual Meeting that support CX-801’s mechanism of action and the ongoing combination study with KEYTRUDA